peptide analog comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-02-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
A Russian S-300 missile hit a museum in Kupiansk, Kharkiv Oblast, killing two people and wounding ten others. Natalia Humeniuk, the spokeswoman for Ukraine's Southern Defense Forces, stated that they had destroyed between 13 and 20 pieces of Russian military equipment on the left (east) bank of the Dnipro River each day over the last three days, and had inflicted heavy losses on the enemy.
=== Allergy === Molecular diagnostics is increasingly used in allergology, especially for food and respiratory allergy. Conventional diagnosis is based on clinical history, skin-prick testing and measurement of serum allergen-specific IgE to whole allergen extracts. Molecular-based allergy diagnostics, also called component-resolved diagnostics, measures IgE to individual allergen molecules rather than only to extracts. This can help distinguish genuine sensitization from cross-reactivity, refine assessment of clinical risk in some allergies, and support decisions about allergen immunotherapy. Multiplex platforms, such as Allergy Explorer (ALEX), can test IgE reactivity to many allergen extracts and molecular components in a single assay. Precision allergy molecular diagnosis (PAMD®) is a broader diagnostic approach using molecular IgE profiles to guide prognosis, risk assessment and personalized management, although results must be interpreted together with the patient’s clinical history.
Regarding this, San Francisco attorney Alex Coolman has commented, "It's remarkable that Chidester's parents, and only Chidester's parents, continue to be cited over and over again by the mainstream media in their coverage of the supposed 'controversy' over the risks of Salvia divinorum." Kathleen Chidester has continued campaigning for "Schedule I"-like legislation beyond their home state of Delaware. For example, three years after Brett's death, in written testimony in support of Senator Richard Colburn's proposed Senate Bill to the Maryland State Legislature, saying, "My hope and goal is to have salvia regulated across the US. It's my son's legacy and I will not end my fight until this happens."
TAB2 in turn serves as a beacon for the recruitment of MEKK1 which then dismisses the N-CoR complex and derepresses its target gene, in effect converting bicalutamide into an AR agonist. This mechanism does not rely on mutations in the LBD of the AR.
=== Cardiovascular outcomes in type 2 diabetes === A major focus of McGuire's research has been understanding how antihyperglycemic therapies for type 2 diabetes affect cardiovascular risk. His work has helped establish the modern framework of cardiovascular outcome trials (CVOTs), emphasizing the need to demonstrate not only glycemic control but also cardiovascular safety and benefit. He has written on the evolving ethical and scientific challenges of trial design in an era when a number of antihyperglycemic medications have shown cardiovascular protection, advocating for creative trial designs for randomized assessment of novel agents against active comparators with established evidence of efficacy.
Sources: en.wikipedia.org
Over-expression of human wild-type or A53T-mutant alpha-synuclein in primates drives deposition of alpha-synuclein in the ventral midbrain, degeneration of the dopaminergic system and impaired motor performance. Although the accumulation and aggregation of alpha-synuclein in most Parkinson's disease patients primarily result from posttranscriptional mechanisms, targeting its production remains a potential therapeutic approach. Research indicates that microRNA-7 and the naturally occurring small molecule quercetin can reduce alpha-synuclein levels under experimental conditions. Certain sections of the alpha-synuclein protein may play a role in the tauopathies. In children with autism spectrum disorders, the serum levels of alpha-synuclein have been reported to be significantly higher. A correlation to higher levels of e.coli and pro-inflammatory gut microbiome in those patients and an approach through disease modifying polysaccharides has been reported in clinical pilot studies. A prion form of the protein alpha-synuclein may be a causal agent for the disease multiple system atrophy.
At Leeds Crown Court, Piran Ditta Khan, who planned the 2005 robbery during which PC Sharon Beshenivsky was shot dead, is convicted of her murder. He is the last of the seven-member gang involved in the robbery to stand trial. The deadline for installing new scanners at airports is extended, meaning airline passengers at major airports will continue to face limits on the amount of liquid they can carry in hand luggage. The Met Office issues a yellow severe weather warning for wintry showers and high winds ahead of the arrival of Storm Kathleen, expected to reach the UK on 6 April. 5 April – John Tinniswood, a great-grandfather from Merseyside, officially becomes the world's oldest living man at the age of 111 years and 283 days. 6 April Former Prime Minister Boris Johnson describes calls for the UK to end arms sales to Israel as "shameful". Two planes collide at Heathrow Airport causing damage to both aircraft, but there are no injuries to people on board. 7 April Deputy Prime Minister Oliver Dowden tells the BBC he still believes it is legal for the UK to sell arms to Israel. Analysis by BBC News suggests that those running the Post Office were paid £19.4m during the 24 years of the Horizon IT scandal. 8 April Westernmost parts of the UK experience a partial solar eclipse. William Wragg steps down as vice chairman of the 1922 Committee of Tory MPs, after sharing MPs' personal phone numbers with someone on a dating app. 9 April Widespread travel and other disruption is reported around the UK, following an exceptionally high tide combined with strong winds.
Restriction digest is the intentional laboratory breaking of DNA strands. It is an enzyme-based treatment used in biotechnology to cut DNA into smaller strands in order to study fragment length differences among individuals or for gene cloning. This method fragments DNA either by the simultaneous cleavage of both strands, or by generation of nicks on each strand of dsDNA to produce dsDNA breaks. Acoustic shearing of the transmission of high-frequency acoustic energy waves delivered to a DNA library. The transducer is bowl shaped so that the waves converge at the target of interest. Nebulization forces DNA through a small hole in a nebulizer unit, which results in the formation of a fine mist that is collected. Fragment size is determined by the pressure of the gas used to push the DNA through the nebulizer, the speed at which the DNA solution passes through the hole, the viscosity of the solution, and the temperature. Sonication, a type of hydrodynamic shearing, subjects DNA to acoustic cavitation and hydrodynamic shearing by exposure to brief periods of sonication, usually resulting in 700bp fragments. For DNA fragmentation, sonication is commonly applied at burst cycles using a probe-type sonicator. Point-sink shearing, a type of hydrodynamic shearing, uses a syringe pump to create hydrodynamic shear forces by pushing a DNA library through a small abrupt contraction. About 90% of fragment lengths fall within a two-fold range. Needle shearing creates shearing forces by passing DNA libraries through small gauge needle.
Menopur, 5 mL vials containing 75 IU FSH and 75 IU LH. Repronex, vials containing either 75 IU FSH and 75 IU LH, or 150 IU FSH and 150 IU LH. Common side effects of preparations containing FSH and LH are:
LTE4 >> LTC4 = LTD4 > α-ketoglutarate = itaconate. It may be difficult to determine if an OXGR1-stimulating agent elicits a functional response by activating OXGR1 as opposed to some other mechanism. To make this distinction, studies have shown that the action of an OXGR1-activating agent on cultured cells, cultured tissues, or animals does not occur or is reduced when these cells, tissues, or animals have been altered so that they do not express or express greatly reduced levels of the OXGR1 protein, or when their actions are inhibited by an OXGR1 receptor antagonists. OXGR1 is inhibited by montelukast, a well-known inhibitor of the cysteinyl leukotriene receptor 1, i.e., the receptor for LTD4, LTC4, and LTE4. Montelukast also blocks the binding of these leukotrienes to, and thereby inhibits their activation of, OXGR1. One study presented evidence suggesting that α-ketoglutarate binds to OXGR1. It is assumed that montelukast similarly blocks α-ketoglutarate's binding to, and thereby inhibits its activation of OXGR1.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.